Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate ...

The role of liquid biopsies in prostate cancer management

The efficient isolation of circulating biomarkers is often the first step to perform a liquid biopsy-based clinical study. This section will ...

Abstracts and Posters | New Frontiers in Liquid Biopsies

... based liquid biopsy test for circulating ... metastatic castration-resistant prostate cancer over immunotherapy using circulating tumor DNA.

EDITORIAL - The Canadian Journal of Urology

and not represent advanced disease or a tumor cell? With the current interest in the liquid biopsy for prostate cancer, other newly discovered entities such ...

Liquid biopsy tumor heterogeneity test predicts resistance to ...

Liquid biopsy tumor heterogeneity test predicts resistance to targeted therapy in metastatic prostate cancer patients. LinkedIn. Share.

Hunting for traces of cancer in blood - QIAGEN

The US Food and Drug Administration approved the first liquid biopsy test in 2013 to monitor patients with advanced metastatic breast, colon, and prostate ...

Analysis of Circulating Tumor DNA to Monitor Metastatic Breast ...

Therefore, there is an urgent need for biomarkers that measure tumor burden with high sensitivity and specificity. Cancer antigen 15-3 (CA 15-3) ...

The Translational Status of Cancer Liquid Biopsies

Liquid biopsy can target diverse classes of biomarkers, such as circulating tumor cells (CTC), circulating free and tumor DNA (cfDNA and ctDNA, ...

Liquid biopsy: a step forward towards precision medicine in urologic ...

In this review, we provide an overview of the current state of cell-free DNA-based kidney, prostate and bladder cancer biomarker research and ...

Classifying prostate cancer subtypes from liquid biopsies

... metastatic castration-resistant prostate cancer subtypes from circulating tumor DNA ... liquid biopsies” may replace invasive needle-based ...

Circulating Biomarkers Predictive of Treatment Response in Patients ...

Metastatic prostate cancer (mPCa) harbors genomic alterations that may predict targeted therapy efficacy. These alterations can be ...

Circulating tumor cells et al.: towards a comprehensive liquid biopsy ...

It is becoming evident that combining diverse circulating biomarkers, each representing different facets of tumor biology, has the potential to ...

Performance of a blood-based liquid biopsy test to detect PSMA ...

Performance of a blood-based liquid biopsy test to detect PSMA expression on circulating tumor cells in men with metastatic prostate cancer.

Quantitative and Qualitative Analysis of Blood-based Liquid ...

Primary prostate tumor biopsies,althoughroutine,areoftenscantin yield,andfixation procedures impact DNA quality. Biopsies of osteoblastic metastatic lesions, on ...

Circulating Tumor DNA and Circulating Tumor Cells for Cancer ...

biopsy for metastatic prostate cancer are addressed in separate reviews. ... Certain liquid biopsy-based assays have been cleared or ...

Full article: Liquid biopsy: paving a new avenue for cancer research

The clinical significance of CTCs as biomarkers for treatment response and prognosis has been extensively investigated. In particular, in patients with advanced ...

The Potential of Circulating Tumor Cells as a Liquid Biopsy to Guide ...

In general, several studies have indicated that CTC counts predict the prognosis of patients with metastatic prostate cancer, whereas the relevance in patients ...

the next generation of biomarkers for liquid biopsy-based prostate ...

Prostate cancer (PCa) is a leading cause of cancer death for males in western countries. The current gold standard for PCa diagnosis - template needle ...

Circulating tumor DNA in patients with metastatic prostate cancer ...

The authors found that baseline detectable ctDNA concentration is an independent, predictive biomarker of outcome during abiraterone therapy and ...

Liquid Biopsy: What It Is & Procedure Details - Cleveland Clinic

Cell Search® Circulating Tumor Cell (CTC) Test detects CTCs. It's used to predict the likely outcome for people with metastatic breast, prostate ...

Ushering in a New Era of Personalized Treatment for Advanced ...

Outside of helping you interpret liquid biopsy results, ctDNA tumor fraction is emerging as a potentially powerful new biomarker in prostate ...